UBS initiated coverage of Centene with a Neutral rating and $72 price target. UBS thinks Centene’s revised FY24 EPS target of $6.60 now more appropriately reflects known risks in MA/Medicaid, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNC:
- Centene falls -8.2%
- Centene to sell Apixio, terms undisclosed
- CENTENE CORPORATION SIGNS DEFINITIVE AGREEMENT TO DIVEST APIXIO TO NEW MOUNTAIN CAPITAL
- Centene price target lowered to $87 from $95 at Stephens
- Centene price target lowered to $87 from $94 at Credit Suisse
Questions or Comments about the article? Write to editor@tipranks.com